



The Commonwealth of Massachusetts  
Executive Office of Health and Human Services  
Department of Public Health  
250 Washington Street, Boston, MA 02108-4619


CHARLES D. BAKER  
Governor

KARYN E. POLITO  
Lieutenant Governor

MARYLOU SUDDERS  
Secretary

MONICA BHAREL, MD, MPH  
Commissioner

Tel: 617-624-6000  
[www.mass.gov/dph](http://www.mass.gov/dph)



TO: Boards of Health

FROM: Susan T. Gershman, MPH, PhD, CTR *SG*  
Director  
Massachusetts Cancer Registry

DATE: January 25, 2019

RE: Cancer Incidence in Massachusetts, 2010-2014, City and Town Supplement  
Cancer Incidence in Massachusetts, 2011-2015, City and Town Supplement

I am writing to inform you that the Massachusetts Cancer Registry (MCR) of the Massachusetts Department of Public Health (MDPH) is releasing two reports:

*Cancer Incidence in Massachusetts, 2010-2014, City and Town Supplement, and  
Cancer Incidence in Massachusetts, 2011-2015, City and Town Supplement.*

Please note that these reports will be published in an electronic version only and will be posted on the Department of Public Health's web site at [www.mass.gov/dph/mcr](http://www.mass.gov/dph/mcr) on February 8, 2019. If you are interested in further supplement data prior to the posting, please contact the registry directly at the telephone number listed below. Please note that there is no embargo on these data and they may be released prior to the web posting date.

The 2010-2014 City and Town Supplement and the 2011-2015 City and town Supplement are updates to the City and Town Supplement series. For each city and town, these reports provide expected case counts, observed case counts, standardized incidence ratios, and confidence intervals for 23 types of cancer and for all cancers combined. The confidence intervals indicate if there is a statistically significant difference (excess or deficit) between the observed and expected counts.

We are providing you with the following pieces of information in advance of the reports' Internet release.

1. The introduction to the report, including an explanation of standardized incidence ratios.

*over*

2. The cancer incidence data for your town (i.e. for 23 cancer types and all cancers combined) for the two time periods: 2010-2014 and 2011-2015.
3. Appendix II includes selected resources for information on cancer.
4. Appendix III includes MDPH Cancer Prevention and Control Initiatives.

For cancer risk factors, please check the following websites: American Cancer Society: [www.cancer.org](http://www.cancer.org); National Cancer Institute: [www.cancer.gov](http://www.cancer.gov).

The complete Internet version will be available at: [www.mass.gov/dph/mcr](http://www.mass.gov/dph/mcr) on February 8, 2019. If you have any trouble accessing this web site, please contact the MCR at (617) 624-5642.

For further information, please contact the following at MDPH:

Massachusetts Cancer Registry (617) 624-5642  
Bureau of Environmental Health (617) 624-5757  
Massachusetts Comprehensive Cancer Prevention and Control Program (617) 624-5484

## INTRODUCTION

### Content

The purpose of this report is to provide an estimate of cancer incidence for each of the 351 cities and towns of Massachusetts for the five-year time period 2011 through 2015. For each city and town, Standardized Incidence Ratios (SIRs) are presented for twenty-three types of invasive cancer and for all invasive cancer types combined. These ratios compare the cancer incidence experience of each city or town with the cancer experience of the state as a whole. The method involves comparing the number of cases that were observed for a city or town to the number of cases that would be expected if the city or town had the same cancer rates as the state as whole. The report is organized into the following sections:

**METHODS** provides a detailed explanation of the data collection, data processing, and statistical techniques employed in this report.

**TABLES** present data for selected types of cancer by city/town and sex.

**APPENDIX I** provides a listing of *International Classification of Diseases for Oncology* codes used in the preparation of this report.

**APPENDIX II** provides selected resources for information on cancer.

**APPENDIX III** describes the Massachusetts Department of Public Health's current cancer control initiatives, and provides links to bureaus within the department that address some aspect of cancer. Links to resources for publications are also provided.

### Comparison with Previous Reports

This report updates previous annual reports published by the Massachusetts Cancer Registry (MCR). It is available on line at <http://www.mass.gov/dph/mcr>. For questions about the report, contact the MCR at:

Massachusetts Cancer Registry  
Office of Data Management and Outcomes Assessment  
Office of Population Health  
Massachusetts Department of Public Health  
250 Washington Street, 6<sup>th</sup> floor  
Boston, MA 02108-4619  
telephone 617-624-5642; fax 617-624-5695

The preceding report, *Cancer Incidence in Massachusetts 2010-2014: City and Town Supplement*, included data for diagnosis years 2010 through 2014. This report contains data for the diagnosis years 2011 through 2015. There have been no changes in this report's format from the previous report.

## METHODS

### Data Sources

#### *Cancer Incidence*

The MCR collects reports of newly diagnosed cancer cases from health care facilities and practitioners throughout Massachusetts. Facilities that reported the 2011-2015 diagnoses that comprise this report include 69 Massachusetts acute care hospitals, 20 independent laboratories, 10 surgical centers, 5 radiation/oncology centers, 10 medical practice associations, 4 endoscopy centers, and approximately 500 private practice physicians. The MCR signed the modified National Data Exchange Agreement on March 28, 2013. This is a single agreement that allows participating states to exchange data on cases diagnosed or treated in other areas. Together with states participating in the agreement, and states with individual agreements, the MCR now has reciprocal reporting agreements with 42 states and with the District of Columbia, the Virgin Islands, Puerto Rico and Guam to obtain data on Massachusetts residents diagnosed out of state. Currently the MCR collects information on *in situ* and invasive cancers and benign tumors of the brain and associated tissues. The MCR does not collect information on basal and squamous cell carcinomas of the skin.

The MCR also collects information from reporting hospitals on cases diagnosed and treated in staff physician offices when this information is available. Not all hospitals report this type of case, however, some hospitals report such cases as if the patients had been diagnosed and treated by the hospital directly. Collecting these types of data makes the MCR's overall case ascertainment more complete. Some cancer types that may be reported to the MCR in this manner are melanoma, prostate, colon/rectum, and oral cancers.

In addition, the MCR identifies previously unreported cancer cases through review of death certificate data to further improve case completeness. This process is referred to as death clearance and identifies cancers mentioned on death certificates that were not previously reported to the MCR. In some instances, the MCR obtains additional information on these cases through follow-up activities with hospitals, nursing homes, hospice residences, and physicians' offices. In other instances, a cancer-related cause of death recorded on a Massachusetts death certificate is the only source of information for a cancer case. Thus these "death certificate only" cancer diagnoses are poorly documented and have not been confirmed by review of clinical and pathological information. Such cases are included in this report, but they comprise less than 3% of all cancer cases.

All case reports that provided the basis for this report were coded following the *International Classification of Diseases for Oncology, Third Edition* (ICD-O-3), which was implemented in North America with cases diagnosed as of January 1, 2001. (1) Please see Appendix A for the classification of cancers by ICD-O3 codes.

Each year, the North American Association of Central Cancer Registries (NAACCR) reviews cancer registry data for quality, completeness, and timeliness. For 2011-2015, the MCR's annual case count was estimated by NAACCR to be more than 95% complete for each year. The MCR has achieved the gold standard for this certification element as well as for six other certification elements for each case year since 1997.

The Massachusetts cancer cases presented in this report are primary cases of cancer diagnosed among Massachusetts residents during 2011-2015 and reported to the MCR as of June 26, 2018. These data include some additional cases diagnosed in 2010-2014 that were not counted in the

previous report, *Cancer Incidence in Massachusetts 2010-2014: City and Town Supplement*. The lag time between this report and the annual statewide report of 2011-2015 cancer cases is due to the fact that data for this city and town report needed to be cleaned for accuracy of residence within Massachusetts. The statewide report presented data at the state level and did not require such accuracy of city and town of residence. The numbers presented in this report may change slightly in future reports, reflecting late reported cases or corrections based on subsequent details from the reporting facilities. Such changes might result in slight differences in numbers and rates in future reports of MCR data, reflecting the nature of population-based cancer registries that receive case reports on an ongoing basis.

Massachusetts cancer cases presented in this report are primary cases of cancer diagnosed among Massachusetts residents during 2011-2015. The Massachusetts data presented include invasive cancers only (except cancer of the urinary bladder, where *in situ* cancers are also included). Invasive cancers have spread beyond the layer of cells where they started and have the potential to spread to other parts of the body. *In situ* cancers are neoplasms diagnosed at the earliest stage, before they have spread, when they are limited to a small number of cells and have not invaded the organ itself. Typically, published incidence rates do not combine invasive and *in situ* cancers due to differences in the biologic significance, survival prognosis and types of treatment of the tumors. Cancer of the urinary bladder is the only exception, due to the specific nature of the diagnostic techniques and treatment patterns.

### **Presentation of Data**

Each city and town in Massachusetts is listed alphabetically in the **TABLES** section. The observed number of cases, the expected number of cases, the standardized incidence ratios, and 95% confidence intervals are presented for twenty-three main types of cancer and for all cancer types combined. The “all cancers combined” category includes the twenty-three main types presented in this report and other malignant neoplasms. This category is meant to provide a summary of the total cancer experience in a community. As different cancers have different causes, this category does not reflect any specific risk factor that may be important for this community.

### ***Observed and Expected Case Counts***

The *observed* case count (**Obs**) for a particular type of cancer in a city/town is the actual number of newly diagnosed cases among residents of that city/town for a given time period.

A city/town’s *expected* case count (**Exp**) for a certain type of cancer for this time period is a calculated number based on that city/town’s population distribution<sup>2</sup> (by sex and among eighteen age groups) for the time period 2011-2015, and the corresponding statewide average annual age-specific incidence rates. The source of the city and town population data for the 2011-2015 period was the US Census American Community Survey (ACS), an ongoing national survey that provides demographic estimates on a yearly basis.<sup>2</sup>

### ***Standardized Incidence Ratios***

A Standardized Incidence Ratio (SIR) is an indirect method of adjustment for age and sex that describes in numerical terms how a city/town's cancer experience in a given time period compares with that of the state as a whole.

- An SIR of *exactly 100* indicates that a city/town's incidence of a certain type of cancer is *equal to that expected* based on statewide average age-specific incidence rates.
- An SIR of *more than 100* indicates that a city/town's incidence of a certain type of cancer is *higher than expected* for that type of cancer based on statewide average annual age-specific incidence rates. For example, an SIR of 105 indicates that a city/town's cancer incidence is 5% higher than expected based on statewide average annual age-specific incidence rates.
- An SIR of *less than 100* indicates that a city/town's incidence of a certain type of cancer is *lower than expected* based on statewide average age-specific incidence rates. For example, an SIR of 85 indicates that a city/town's cancer incidence is 15% lower than expected based on statewide average annual age-specific incidence rates.

### ***Statistical Significance and Interpretation of SIRs***

The interpretation of the SIR depends on both how large it is and how stable it is. Stability in this context refers to how much the SIR changes when there are small increases or decreases in the observed or expected number of cases. Two SIRs may have the same size but not the same stability. For example, an SIR of 150 may represent 6 observed cases and 4 expected cases, or 600 observed cases and 400 expected cases. Both represent a 50 percent excess of observed cases. However, in the first instance, one or two fewer cases would change the SIR a great deal, whereas in the second instance, even if there were several fewer cases, the SIR would only change minimally. When the observed and expected numbers of cases are relatively small, their ratio is easily affected by one or two cases. Conversely, when the observed and expected numbers of cases are relatively large, the value of the SIR is stable.

A 95 percent confidence interval (CI) has been presented for each SIR in this report (when the observed number of cases is at least 5), to indicate if the observed number of cases is significantly different from the expected number, or if the difference is most likely due to chance. A confidence interval is a range of values around a measurement that indicates the precision of the measurement. In this report, the 95% confidence interval is the range of estimated SIR values that has a 95% probability of including the true SIR for a specific city or town. If the 95% confidence interval range *does not* include the value 100.0, then the number of observed cases is significantly different from the expected number of cases. "Significantly different" means there is at most a 5% chance that the difference between the number of observed and expected cancer cases is due solely to chance alone. If the confidence interval does contain the value 100.0, there is no significant difference between the observed and expected numbers. Statistically, the width of the interval reflects the size of the population and the number of events; smaller populations and smaller observed numbers of cases yield less precise estimates that have wider confidence intervals. Wide confidence intervals indicate instability, meaning that small changes in the observed or expected number of cases would change the SIR a great deal.

Examples:

- SIR = 137.0; 95% CI (101.6 - 180.6) – the confidence interval does not include 100.0 and the interval is above 100.0, indicating that the number of observed cases is *statistically significantly higher* than the expected number.
- SIR = 71.0; 95% CI (56.2 – 88.4) – the confidence interval does not include 100.0 and the interval is below 100.0, indicating that the number of observed cases is *statistically significantly lower* than the expected number.
- SIR = 108.8 95% CI (71.0-159.4) – the confidence interval DOES include 100.0 indicating that the number of observed cases is *NOT statistically significantly different* from what is expected, and the difference is likely due to chance. When the interval includes 100.0, then the true SIR may be 100.0.

**Example of Calculation of an SIR and Its Significance**

$$SIR = \frac{\text{OBSERVED CASES}}{\text{EXPECTED CASES}} \times 100$$

The following example illustrates the method of calculation for a hypothetical town for one type of cancer and one sex for the years 2007-2011:

Age Group	<u>Town X</u> Population (A)	<u>State</u> Age-Specific Incidence Rate (B)	<u>Town X</u> Expected Cases (C)=(A) x (B)	<u>Town X</u> Observed Cases (D)
00-04	74,657	0.0001	7.47	11
05-09	134,957	0.0002	26.99	25
10-14	54,463	0.0005	27.23	30
15-19	25,136	0.0015	37.70	40
20-24	17,012	0.0018	30.62	30
<b>UP TO</b>				
85+	6,337	0.0010	6.34	8
		<b>Total:</b>	<b>136.35</b>	<b>144</b>

$$SIR = \frac{\text{Observed Cases}}{\text{Expected Cases}} \times 100 = \frac{(\text{column D total})}{(\text{column C total})} \times 100 = \frac{144}{136.35} \times 100 \approx 106$$

Thus the SIR for this type of cancer in Town X is 106, indicating that the incidence of this cancer in Town X is 6% higher than the corresponding statewide average incidence for this cancer. However, the range for the 95% confidence interval (89.1-124.3) (calculation not shown) indicates that the true value may be as low as 89.1 or as high as 124.3 Also, since the range

includes the value 100, it means that the observed number of cases is *not statistically significantly higher or lower* than what is expected.

Whenever the number of observed cases is less than five, the corresponding SIR is neither calculated nor tested for statistical significance. This is indicated with an (nc) (“not calculated”). However, the number of observed and expected cases is shown in these circumstances.

### **Notes about Data Interpretation**

The SIR is a useful indication of the disease categories that have relatively high or low rates for a given community. These statistics, however, should be used with care. Such statistics provide a starting point for further research and investigation into a possible health problem, but they do not by themselves confirm or deny the existence of a particular health problem. Many factors unrelated to disease causation may contribute to an elevated SIR, including demographic factors, changes in diagnostic techniques, and changes in data collection or recording methods over time, as well as the natural variation in disease occurrence.

When reviewing the data tables, it is important to keep in mind that an SIR compares the observed cancer incidence in a particular community with the expected incidence based on statewide average annual age-specific incidence rates. This means that *valid comparisons can only be made between a community and the state as a whole. SIRs for different cities and towns CANNOT and SHOULD NOT be compared to each other.* (Comparisons between two communities would be valid only if there were no differences in the age and sex distributions of the two communities’ populations.)

Another point to keep in mind when reviewing these data is the large number of statistical tests being performed in this report. For each of the 351 cities and towns, we evaluate 18 types of cancer that can occur in both males and females, 3 types that occur only in females and 2 types that occur only in males, resulting in 41 gender/cancer categories. This results in 14,391 possible calculations (351 cities and towns x 41 gender cancer categories). Note that gender/cancer categories with less than 5 observed cases are not evaluated for statistical significance, so the actual numbers of tests is slightly lower than 14,391. This is important for the reader because when multiple significance tests are performed, some will result in a significant finding due to chance alone. Based on the number of calculations in this report, we expect 720 significant findings to be due to chance alone. Half of these would be significant excesses (360) and half would be significant deficits (360). There are statistical techniques that can be used to reduce this number, however use of these techniques leads to the opposite problem – true significant differences that may be missed. We choose to err on the side of caution and identify more significant results, knowing that some will be due to chance alone.

### **Data Limitations**

It should be emphasized that apparent increases or decreases in cancer incidence over time might reflect changes in diagnostic methods or case reporting rather than true changes in cancer incidence. Four other limitations must be considered when interpreting cancer incidence data for Massachusetts cities and towns: under-reporting in areas close to neighboring states; under-reporting for cancers that may not be diagnosed in hospitals; cases being assigned to incorrect cities/towns; and standardized incidence ratios based on small numbers of cases.



### ***Border Areas and Neighboring States***

Some areas of Massachusetts appear to have low cancer incidence, but this may be due to loss of Massachusetts resident cases who are diagnosed in neighboring or other states and not reported to the MCR. The MCR has reciprocal reporting agreements with 42 states and with the District of Columbia, the Virgin Islands, Puerto Rico, and Guam.

### ***Cases Diagnosed in Non-Hospital Settings***

During the time period covered by this report, the MCR's primary information source for most newly diagnosed cases of cancer was hospitals. In addition the MCR collected information from reporting hospitals on cases diagnosed and treated in staff physician offices, when this information was available. Other reporting sources include dermatologists and dermatopathology laboratories, urologists' offices and a general laboratory. Some types of cancer in this report may be under-reported because they are diagnosed primarily by private physicians, private laboratories, health maintenance organizations, radiotherapy centers that escape identification systems used by hospitals. The most common types of cancer diagnosed or treated outside of the hospital include melanoma and prostate cancer. The exact extent of this under-reporting has not been determined, but cases included in this report represent the great majority of cases statewide and provide an essential basis for evaluating statewide cancer incidence patterns.

### ***City/Town Misassignment***

In accordance with standard central cancer registry procedures, each case reported to the MCR ideally should be assigned to the city/town in which the patient lived at the time of diagnosis, based on the address provided by the reporting hospital. In practice, however, a patient may provide the hospital with his/her mailing address (e.g., a post office box located outside the patient's city/town of residence); a business address; a temporary address (e.g., the patient is staying with a relative while receiving treatment and reports the relative's address as his/her own); or a locality or post office name (e.g., "Chestnut Hill" rather than "Boston," "Brookline," or "Newton"). In addition, if a patient has moved since being diagnosed, the hospital may report the patient's current address. Because of the large number of cases reported to the MCR, and because data are reported to the MCR via electronic media, most city/town case assignments are performed by an automated computer process. This simplified matching process may misassign some cases based on the reported locality name. When MCR staff become aware of such misassignments, they manually correct the errors. Furthermore, in order to minimize such errors, cases from fifty geographic localities prone to city/town misassignment are reviewed manually.

### ***Small Numbers of Cases***

Standardized incidence ratios based on small numbers of cases result in estimates that are very unstable. This situation is common when the population of a city or town is small or if the particular cancer type is rare. SIRs and statistical significance are not calculated when the number of observed cases for a specific category is less than five. In these instances, the observed and expected cases are presented in the tables *for qualitative comparison only*.

This page intentionally left blank.

## APPENDIX II: SELECTED RESOURCES FOR INFORMATION ON CANCER

This Appendix contains a listing of selected resources for additional information on cancer. Cancers are complex diseases, many of which have multiple factors that may contribute to their development.

For information on cancer risk factors or prevention, you may wish to contact the following:

Cancer Information Service (National Cancer Institute): 1-800-4-CANCER (1-800-422-6237)

Cancer Response Line (American Cancer Society): 1-800-ACS-2345 (1-800-227-2345)

In addition, the following selected Internet websites provide information on cancer. Many of these also provide links to other sites (not listed) which may be of interest.

**Massachusetts Department of Public Health:** <http://www.mass.gov/dph>

**American Cancer Society:** <http://www.cancer.org>

### **Centers for Disease Control and Prevention**

Home Page: <http://www.cdc.gov>

Cancer Prevention and Control Program: <http://www.cdc.gov/cancer>

Fruits and Veggies More Matters™ Campaign (nutrition – formerly 5-A-Day Program):  
<http://www.fruitsandveggiesmorematters.org/>

### **National Cancer Institute**

Information: <http://www.cancer.gov>

Cancer Literature in PubMed:

[https://www.ncbi.nlm.nih.gov/pubmed?cmd=current&pmfilter\\_Subsets=Cancer](https://www.ncbi.nlm.nih.gov/pubmed?cmd=current&pmfilter_Subsets=Cancer)

Surveillance, Epidemiology, and End Results (SEER) Program data: <http://seer.cancer.gov>

**Your Cancer Risk** (Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; formerly at Harvard Center for Cancer Prevention):  
<http://www.yourdiseaserisk.wustl.edu>

**OncoLink** (Abramson Cancer Center of the University of Pennsylvania):  
<http://www.oncolink.org>

**Cancerquest** (Emory University – Winship Cancer Institute): [www.cancerquest.org](http://www.cancerquest.org)

**National Coalition for Cancer Survivorship:** <http://www.canceradvocacy.org>

### APPENDIX III: MDPH CANCER PREVENTION AND CONTROL INITIATIVES

The Massachusetts Department of Public Health is working to reduce the incidence and mortality of cancer in the Commonwealth. Partnerships between MDPH programs, researchers, healthcare providers and nonprofit organizations collect information about cancer, lead quality improvement projects, coordinate evidenced-based workshops for managing living with chronic disease (including cancer), provide education for health professionals and bring shared messages to the public. Our collaborated efforts focus on reducing cancer risk, incidence and mortality through healthy lifestyles, early diagnosis, and increased access to care. The Department's programs address the impact of tobacco, alcohol, nutrition, and physical activity on cancer prevention, along with environmental and occupational hazards for cancer. Throughout all of our efforts there is an emphasis on reducing disparate health outcomes and unequal access to cancer care.

#### MDPH Bureaus and Programs:

Bureau of Environmental Health, [www.mass.gov/dph/environmental\\_health](http://www.mass.gov/dph/environmental_health)

Bureau of Substance Abuse Services, [www.mass.gov/dph/bsas](http://www.mass.gov/dph/bsas)

Comprehensive Cancer Prevention and Control Program, [www.mass.gov/compcancer](http://www.mass.gov/compcancer)

Men's Health/Women's Health/Care Coordination Program

Tobacco Cessation and Prevention Program, [www.mass.gov/dph/mtcp](http://www.mass.gov/dph/mtcp)

Occupational Health Surveillance Program, [www.mass.gov/dph/ohsp](http://www.mass.gov/dph/ohsp)

Office of Elder Affairs [www.mass.gov/elders/](http://www.mass.gov/elders/)

Oral Health Program, [www.mass.gov/dph/oralhealth](http://www.mass.gov/dph/oralhealth)

Division of Prevention and Wellness [www.mass.gov/dph/healthpromotion](http://www.mass.gov/dph/healthpromotion)

MDPH publications on cancer prevention and screening are available at the Massachusetts Health Promotion Clearinghouse, [www.maclclearinghouse.com](http://www.maclclearinghouse.com).

Massachusetts Cancer Registry Publications are available through the Massachusetts Cancer Registry, telephone: 617-624-5642 and on the web at [www.mass.gov/dph/mcr](http://www.mass.gov/dph/mcr).

# Norfolk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2010-2014

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	11.4	70.4	(30.3-138.8)	Male	20	8.6	233.1	(142.3-360.0)
Female	1	2.5	nc	(nc-nc)	Female	4	4.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	2.8	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	5	7.6	65.8	(21.2-153.5)
Female	42	37.2	112.9	(81.4-152.7)	Female	1	4.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.3	nc	(nc-nc)	Male	5	7.3	68.2	(22.0-159.1)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	12	14.0	85.6	(44.2-149.5)	Female	1	3.1	nc	(nc-nc)
Female	7	7.8	90.3	(36.2-186.0)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	4.5	nc	(nc-nc)
Male	6	3.5	170.5	(62.3-371.1)	Female	2	2.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	40	45.7	87.4	(62.5-119.1)
Male	0	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	1.0	nc	(nc-nc)
Male	11	8.3	133.3	(66.5-238.5)	<b><u>Testis</u></b>				
Female	4	2.7	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	4	2.1	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	8	7.2	110.5	(47.6-217.8)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	5.2	nc	(nc-nc)	Female	5	8.6	58.2	(18.7-135.8)
Female	2	2.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	154	174.6	88.2	(74.8-103.3)
Male	4	5.2	nc	(nc-nc)	Female	103	113.7	90.6	(74.0-109.9)
Female	1	1.0	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	18	21.7	83.0	(49.2-131.2)					
Female	12	14.2	84.6	(43.7-147.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( Obs / Exp ) X 100;
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Norfolk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	13.2	60.8	(26.2-119.8)	Male	24	9.4	255.4	(163.6-380.0)
Female	1	2.8	nc	(nc-nc)	Female	4	4.6	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.9	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	6	8.3	72.4	(26.5-157.7)
Female	41	39.1	105.0	(75.3-142.4)	Female	2	4.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.4	nc	(nc-nc)	Male	6	7.7	77.4	(28.3-168.6)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	9	15.1	59.6	(27.2-113.1)	Female	1	3.2	nc	(nc-nc)
Female	6	8.4	71.8	(26.2-156.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	5	3.8	131.6	(42.4-307.2)	Male	2	5.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	1.2	nc	(nc-nc)	Male	38	47.6	79.8	(56.5-109.5)
Female	0	0.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	12	9.1	131.3	(67.8-229.4)	Male	5	3.3	150.2	(48.4-350.5)
Female	4	2.9	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	3	2.3	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	5	5.7	87.8	(28.3-204.9)	Male	2	4.4	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	10	7.7	129.9	(62.2-239.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	5.6	nc	(nc-nc)	Female	7	9.1	76.9	(30.8-158.4)
Female	1	1.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	16	24.4	65.7	(37.5-106.6)	Male	155	189.1	82.0	(69.6-95.9)
Female	13	15.2	85.4	(45.4-146.1)	Female	105	121.3	86.6	(70.8-104.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

